Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Tuesday, September 12, 2023

Phase I trial of senolytic therapy shows promise in Alzheimer's disease

You might need this. Is your competent doctor closely following this? 

Your risk of dementia, has your doctor told you of this?  Your doctor is responsible for preventing this!

1. A documented 33% dementia chance post-stroke from an Australian study?   May 2012.

2. Then this study came out and seems to have a range from 17-66%. December 2013.`    

3. A 20% chance in this research.   July 2013.

4. Dementia Risk Doubled in Patients Following Stroke September 2018 

The latest here:

Phase I trial of senolytic therapy shows promise in Alzheimer's disease

Alzheimer's disease is the most common cause of dementia that affects more than 6.5 million Americans, according to the Alzheimer's Association. To find effective treatments and slow the progression of this debilitating disease, researchers have made much progress in developing new drugs that target beta-amyloid plaques, one of the hallmarks of Alzheimer's disease.

Beta-amyloid plaques are accumulations of brain protein fragments, which can impact cognition. However, these recent drugs have only yielded modest results.

Now, scientists at Wake Forest University School of Medicine are reporting results from a Phase I trial in another area of promising research-;cellular senescence.

The findings appear online today in Nature Medicine.

Senescent cells are old, sick cells that cannot properly repair themselves and don't die off when they should. Instead, they function abnormally and release substances that kill surrounding healthy cells and cause inflammation. Over time, they continue to build up in tissues throughout the body contributing to the aging process, neurocognitive decline and cancer.

In 2018, we found evidence of senescent cells in human Alzheimer's disease. In mouse models, we also found that they contribute to brain cell loss, inflammation and memory impairment."

Miranda Orr, Ph.D., associate professor of gerontology and geriatric medicine at Wake Forest University School of Medicine

Researchers repurposed a U.S. Food and Drug Administration-approved drug designed to clear cancer cells (dasatinib) in combination with a flavonoid, a plant-derived antioxidant (quercetin).

"Our previous research has shown that the combination of these two drugs target senescent cells and allow them to die," Orr said. "We know that they cleared senescent brain cells in Alzheimer's disease mouse models, and they had already been shown to be safe in patients with other ailments."

For the current study, which was co-led by Mitzi Gonzales, Ph.D., of The University of Texas Health Science Center at San Antonio, the research team enrolled five participants aged 65 and older with symptoms of early-stage Alzheimer's disease. Participants received oral dasatinib plus quercetin over two consecutive days, followed by two weeks of no drugs. The cycle repeated six times for a total of 12 weeks.

"Our primary goal was to determine whether the medicines penetrated the central nervous system," Orr said. "We collected samples of patients' cerebrospinal fluid (CSF) before the first dose of medicine was given and after the last dose of medicine was given."

The research team also collected data on the safety and efficacy of the two drugs by monitoring side effects. They assessed biomarkers of senescence in CSF and blood, and also evaluated patients' cognition and brain images before treatment and after they completed the 12-week study.

They found that both dasatinib and quercetin levels increased in the blood, and dasatinib was detected in the CSF in four subjects. Quercetin was not detected in the CSF of any participants.

"We also determined that the treatment was safe, feasible and well-tolerated," Orr said. "There were no significant changes in brain function as determined by assessing memory and brain imaging to provide additional evidence that it is a safe therapy to evaluate further."

Researchers also saw evidence to suggest that the combination therapy cleared amyloid from the brain and lowered inflammation in the blood.

"However, we shouldn't over-interpret these results," Orr said. "There was a small number of people enrolled, there was no placebo arm to compare results."

Researchers also noted an increase in inflammation in CSF biomarkers. According to Orr, one possible explanation is a transient increase in inflammation when senescent cells are cleared. This increase could also be a marker of senescent cells dying or could potentially indicate inflammation associated with the treatment.

"We will need to monitor this closely in our next trial," said Orr, whose cellular senescence research is currently featured in a special issue of National Geographic focused on aging.

"Dr. Orr's research is a critical part of this pivotal moment in Alzheimer's research as the focus shifts from amyloid and tau, the classic disease hallmarks, toward how the biology of aging underlies the disease," said Howard Fillit, M.D., co-founder and chief science officer at the Alzheimer's Drug Discovery Foundation (ADDF). "Aging is the leading risk factor for Alzheimer's, and it is important that the field explores new approaches for developing therapeutics, like senolytics, that target biological aging. Alzheimer's is a multifaceted disease, and similar to cancer, we will need multiple treatment options that can be combined and personalized to improve the outlook for millions of patients living with Alzheimer's."

Orr's research team is in the process of a larger $3 million, Phase II clinical trial funded by the ADDF to test the effects of clearing senescent cells with the combination therapy.

"We can confidently move forward with a larger study population and placebo arm knowing that the treatment is safe," Orr said. "We will also look forward to learning more about how the treatment may impact Alzheimer's disease biomarkers."

Source:
Journal reference:

Gonzales, M. M., et al. (2023). Senolytic therapy in mild Alzheimer’s disease: a phase 1 feasibility trial. Nature Medicine. doi.org/10.1038/s41591-023-02543-w.

No comments:

Post a Comment